Matthew Brimberry, MD
Family Medicine · Austin, TXNPI 1578791976
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (41.2%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Life Technologies Corporation accounts for 65.3% of it on its own, with 46 other manufacturers making up the rest. Reporting peaked in 2021 at $14,344 and has fallen 93.1% since, to $996 in 2025. Among family medicine clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 335 payments — averaging $61.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Life Technologies Corporation$14K
- AstraZeneca$2K
- Novo Nordisk$965
- AbbVie$540
- Amgen$389
- GSK$342
- plus $2K from 41 others
Across 207 payments — averaging $18,344 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$2.2M
- Genentech, Inc.$568K
- AstraZeneca$502K
- Abbott$193K
- GSK$84K
- Romark Laboratories, LC$79K
- plus $127K from 6 others
What the payments were for
- Consulting fees$5,00024%
- Speaking & faculty fees$8,54841%
- Travel & lodging$1,7188%
- Food & beverage$5,48526%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$20,751 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 22 | $36,025 |
| MounjaroTirzepatide | 23 | $23,368 |
| EliquisApixaban | 22 | $22,850 |
| FarxigaDapagliflozin Propanediol | 18 | $16,617 |
| JardianceEmpagliflozin | 12 | $12,353 |
| Fentanyl | 42 | $9,884 |
| XareltoRivaroxaban | 18 | $9,254 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 177 | $5,004 |
| PaxlovidNirmatrelvir/Ritonavir | 20 | $2,858 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 13 | $2,793 |
| Arnuity ElliptaFluticasone Furoate | 13 | $2,724 |
| Levothyroxine Sodium | 237 | $2,593 |
| Advair DiskusFluticasone Propion/Salmeterol | 13 | $2,501 |
| Atorvastatin Calcium | 300 | $2,336 |
| Gabapentin | 155 | $2,316 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $965 | $36,02522 claims |
| PfizerEliquis, Paxlovid | $231 | $25,70842 claims |
| Lilly USA, LLCMounjaro | $271 | $23,36823 claims |
| AstraZenecaFarxiga | $2,476 | $16,61718 claims |
| Boehringer IngelheimJardiance | $104 | $12,35312 claims |
| Johnson & JohnsonXarelto | $35 | $9,25418 claims |
| AbbVieSynthroid, Armour Thyroid | $540 | $3,36851 claims |
| GSKArnuity Ellipta | $342 | $2,72413 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $13 | $2,593237 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Austin
- Cynthia BrinsonAustin$402K
- David WrightAustin$124K
- Carlos CamposNew Braunfels$1.5M
- Aaron KingSan Antonio$1.1M
- Bradley WassonArlington$734K
- Michael MendezLubbock$368K
- Sang Tae KimAmarillo$368K
- Sumit PerakathuHarlingen$342K
- Joel SolisMcAllen$324K
- Robert CampbellFort Worth$318K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.